Literature DB >> 15194061

Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector.

Samuel K Campos1, M Brandon Parrott, Michael A Barry.   

Abstract

While genetic modification of adenoviral vectors can produce vectors with modified tropism, incorporation of targeting peptides/proteins into the structural context of the virion can also result in destruction of ligand targeting or virion integrity. To combat this problem, we have developed a versatile targeting system using metabolically biotinylated adenoviral vectors bearing biotinylated fiber proteins. These vectors have been demonstrated to be useful as a platform for avidin-based ligand screening and vector targeting by conjugating biotinylated ligands to the virus using high-affinity tetrameric avidin (K(d) = 10(-15) M). The biotinylated vector could also be purified by biotin-reversible binding on monomeric avidin (K(d) = 10(-7) M). In this report, a second metabolically biotinylated adenovirus vector, Ad-IX-BAP, has been engineered by fusing a biotin acceptor peptide (BAP) to the C-terminus of the adenovirus pIX protein. This biotinylated vector displays twice as many biotins and was markedly superior for single-step affinity purification on monomeric avidin resin. However, unlike the fiber-biotinylated vector, Ad-IX-BAP failed to retarget to cells with biotinylated antibodies including anti-CD71 against the transferrin receptor. In contrast, Ad-IX-BAP was retargeted if transferrin, the cognate ligand for CD71, was used as a ligand rather than the anti-CD71. This work demonstrates the utility of metabolic biotinylation as a molecular screening tool to assess the utility of different viral capsid proteins for ligand display and the biology and compatibility of different ligands and receptors for vector targeting applications. These results also demonstrate the utility of the pIX-biotinylated vector as a platform for gentle single-step affinity purification of adenoviral vectors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194061      PMCID: PMC4308313          DOI: 10.1016/j.ymthe.2004.03.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid.

Authors:  A Akalu; H Liebermann; U Bauer; H Granzow; W Seidel
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector.

Authors:  P Reynolds; I Dmitriev; D Curiel
Journal:  Gene Ther       Date:  1999-07       Impact factor: 5.250

3.  Metabolic biotinylation of secreted and cell surface proteins from mammalian cells.

Authors:  M B Parrott; M A Barry
Journal:  Biochem Biophys Res Commun       Date:  2001-03-09       Impact factor: 3.575

Review 4.  Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway.

Authors:  Zhong Ming Qian; Hongyan Li; Hongzhe Sun; Kwokping Ho
Journal:  Pharmacol Rev       Date:  2002-12       Impact factor: 25.468

5.  Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein.

Authors:  Natalya Belousova; Valentina Krendelchtchikova; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

Authors:  T J Wickham; E Tzeng; L L Shears; P W Roelvink; Y Li; G M Lee; D E Brough; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 7.  Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery.

Authors:  A Widera; F Norouziyan; W-C Shen
Journal:  Adv Drug Deliv Rev       Date:  2003-11-14       Impact factor: 15.470

8.  Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

Authors:  Igor P Dmitriev; Elena A Kashentseva; David T Curiel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 9.  Biotinylated gene therapy vectors.

Authors:  Michael A Barry; Samuel K Campos; Debadyuti Ghosh; Kristen E Adams; Hoyin Mok; George T Mercier; M Brandon Parrott
Journal:  Expert Opin Biol Ther       Date:  2003-09       Impact factor: 4.388

10.  Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification.

Authors:  M Brandon Parrott; Kristen E Adams; George T Mercier; Hoyin Mok; Samuel K Campos; Michael A Barry
Journal:  Mol Ther       Date:  2003-10       Impact factor: 11.454

View more
  32 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

2.  Fusion of Large Polypeptides to Human Adenovirus Type 5 Capsid Protein IX Can Compromise Virion Stability and DNA Packaging Capacity.

Authors:  Kathy L Poulin; Emily R McFall; Grace Chan; Natacha B Provost; Carin Christou; Adam C Smith; Robin J Parks
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

Review 3.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

4.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

5.  Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion.

Authors:  Qiana L Matthews; Don A Sibley; Hongju Wu; Jing Li; Mariam A Stoff-Khalili; Reinhard Waehler; J Michael Mathis; David T Curiel
Journal:  Mol Imaging       Date:  2006 Oct-Dec       Impact factor: 4.488

Review 6.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

7.  Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX.

Authors:  Michael P Marsh; Samuel K Campos; Matthew L Baker; Christopher Y Chen; Wah Chiu; Michael A Barry
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Authors:  L Pereboeva; S Komarova; J Roth; S Ponnazhagan; D T Curiel
Journal:  Gene Ther       Date:  2007-01-25       Impact factor: 5.250

9.  The Role of Hexon Protein as a Molecular Mold in Patterning the Protein IX Organization in Human Adenoviruses.

Authors:  Vijay S Reddy
Journal:  J Mol Biol       Date:  2017-07-18       Impact factor: 5.469

10.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.